General form of registration statement for all companies including face-amount certificate companies

INTANGIBLE ASSETS

v3.22.4
INTANGIBLE ASSETS
 9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
INTANGIBLE ASSETS

NOTE 5 – INTANGIBLE ASSETS

 

Intangible assets consisted of the following as of:

 

    Estimated life   September 30,
2022		     December 31,
2021		  
                     
Website   3 years   $ 10,799     $ 10,799  
Website   3 years   $ 10,799     $ 10,799  
Accumulated amortization         (7,799 )     (5,099 )
 Intangible assets, net       $ 3,000     $ 5,700  

 

 

As of September 30, 2022, estimated future amortization expenses related to intangible assets were as follows:

 

         
    Intangible Assets  
2022 (remaining 3 months)   $ 900  
2023     2,100  
 Intangible assets, net   $ 3,000  

 

The Company had amortization expense of $900 and $2,700 and $900 and $15,305 for the three and nine months ended September 30, 2022 and 2021, respectively.

 

On January 8, 2020, James Joyce, the Company’s CEO and Craig Roberts, the Company’s CTO, assigned to the Company the rights to patent 62/881,740 pertaining to the devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood.

 

NOTE 5 – INTANGIBLE ASSETS

 

Intangible assets consisted of the following as of:

 

    Estimated life   December 31, 2021     December 31, 2020  
Trademarks   3 years   $ -     $ 22,060  
Website   3 years     10,799       10,799  
Accumulated amortization         (5,099 )     (10,954 )
        $ 5,700     $ 21,905  

 

As of December 31, 2021, estimated future amortization expenses related to intangible assets were as follows:

 

    Intangible Assets  
2022   $ 3,600  
2023     2,100  
Total   $ 5,700  

 

The Company had amortization expense of $16,205 and $10,954 for the years ended December 31, 2021 and 2020, respectively.

 

On January 8, 2020, James Joyce, the Company’s CEO and Craig Roberts, the Company’s COO, assigned to the Company the rights to patent 62/881,740 pertaining to the devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood.